Biogen’s controversial Alzheimer’s drug generates $2 million gross sales in first few weeks…
Aduhelm from BiogenSource: BiogenBiogen's Alzheimer's drug Aduhelm made $ 2 million in sales in the first few weeks after its approval, the company said Thursday when it released its second quarter results along with an open letter about…